Figure 3 | British Journal of Cancer

Figure 3

From: Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

Figure 3

Kaplan–Meier curves for progression-free survival and overall survival of patients with metastatic renal cell cancer treated with sunitinib: responders (—) and non-responders (- - -) at first evaluation according to Choi criteria (A, B) and the Response Evaluation Criteria in Solid Tumours (RECIST) (C, D) as well as clinical benefit (partial response+stable disease ⩾12 weeks) (—) and no clinical benefit (progressive disease+stable disease <12 weeks) (- - -) at first evaluation by RECIST (E, F).

Back to article page